What one share of Lineage Cell Therapeutics holds
We are a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. Certain diseases and medical events can arise from the loss of critical cellular activity and lead to devastating or difficult-to-treat conditions or impairments.
Lineage Cell Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.05 |
|---|---|
| Profit | −$0.13 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.10 |
| Cash and investments | $0.20 |
| Book value | $0.24 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | $0.09 | −$0.15 | $0.00 | $0.00 | — | $0.43 |
| 2023 | $0.05 | −$0.12 | $0.00 | −$0.17 | — | $0.36 |
| 2024 | $0.05 | −$0.09 | $0.00 | −$0.12 | — | $0.36 |
| 2025 | $0.06 | −$0.28 | $0.00 | −$0.08 | — | $0.18 |
Common questions about Lineage Cell Therapeutics
How much does one share of Lineage Cell Therapeutics earn?
Over the last 12 months, Lineage Cell Therapeutics lost $0.13 for each share on $0.05 of sales.
Does Lineage Cell Therapeutics pay a dividend?
Lineage Cell Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Lineage Cell Therapeutics’s book value per share?
Lineage Cell Therapeutics’s book value is $0.24 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Lineage Cell Therapeutics have?
Each share of Lineage Cell Therapeutics has $0.20 of cash and investments, as of June 30, 2026.
What is Lineage Cell Therapeutics’s free cash flow per share?
−$0.10 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Lineage Cell Therapeutics bought back shares?
Lineage Cell Therapeutics’s share count rose about 36% from 2022 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.